Last reviewed · How we verify
NCT03572140: RAVs
Safety of Sofosbuvir ,Daclatasvir in HCV Patients and RAVS in Resistent and Relapsed Cases
trial testing RAVS In relapsed and resistent cases in HCV in 297 participants. Status unknown.
1 July 2020
Quick facts
| Lead sponsor | Assiut University |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 297 |
| Start date | 1 July 2018 |
| Primary completion | 1 July 2020 |
| Estimated completion | 1 August 2020 |
Drugs / interventions tested
- RAVS In relapsed and resistent cases
Conditions studied
- HCV — all drugs for HCV →
Sponsor
Assiut University
Who can join
Adults 18 to 75, any sex, with HCV. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To identify side effects of Sofosbuvir/ Daclatasvir treatment regimen of chronic HCV GT-4 infection. * To assess the occurrence and the prevalence of RAVs in patients with treatment failure and relapse after sofosbuvir and daclatasvir with assessment of their types . * To examine the GT4 subtypes by phylogenetic analysis and baseline sequence variability among subtypes and their potential impact on treatment outcome and development of viral resistance in patients who received a regimen of Sofosbuvir/ Daclatasvir for treatment of chronic HCV GT-4. * To assess the differences in patient demographics across GT4 subtypes.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03572140
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for HCV
Currently open trials in the same condition.
- NCT07095192 — Scaling Up Point-of-Care Hepatitis C Testing and Treatment in Canada · recruiting
- NCT06316739 — The Ganchero Intervention for Migrant People Who Inject Drugs From Puerto Rico in New York City · NA · active not recruiting
- NCT05794646 — Community Intervention to Eliminate HCV Among People Who Use Drugs. · NA · active not recruiting
- NCT06528626 — Tools to Identify People At Risk or Already Infected with HIV and HCV · NA · recruiting
- NCT05781568 — Use of Blood Biomarkers for the Early Diagnosis of Hepatocellular Carcinoma (HCC) · recruiting
Other Assiut University trials
Trials by the same sponsor.
- NCT07423312 — Lead Exposure and Multiple Sclerosis · not yet recruiting
- NCT07234526 — Usage of Glucose Fluctuations as a Prognostic Marker in Septic Shock Patients · not yet recruiting
- NCT07273214 — Knowledge, Attitude and Practice of Third Trimester Pregnant Mothers Towards Self-Medication in Assiut, Egypt · not yet recruiting
- NCT07194863 — Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD · not yet recruiting
- NCT07053709 — Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD) · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03572140 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Assiut University
- Last refreshed: 29 June 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03572140.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing